O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

INTRODUCTION: Treatment options for recurrent glioblastoma remain limited, with only modest activity of second line chemotherapy. Despite the absence of well controlled trials, bevacizumab is widely used for recurrent glioblastoma. Nonetheless, it remains unclear if the high response rates observed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Taal, W., Oosterkamp, H.M., Walenkamp, A.M.E., Dubbink, H.J., Beerepoot, L.V., Hanse, M., Buter, J., Honkoop, A., Boerman, D., Vos, F.Y.F., Dinjens, W.N.M., Enting, R.H., Taphoorn, M.J.B., van den Berkmortel, F.W.P.J., Jansen, R., Brandsma, D., Bromberg, J.E., van Heuvel, I., Vernhout, R.M., van der Holt, B., van den Bent, M.J.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Oral Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185857/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.86
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados